FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

Rhea-AI Summary

Telix (TLX) reported FY2025 revenue of US$803.8M, up 56% year‑over‑year, adjusted EBITDA of US$39.5M, and a small loss before tax of US$5.3M. Year‑end cash was US$141.9M after US$246.4M of strategic M&A investments.

Precision Medicine revenue rose 22% with stable gross margin (64%). R&D investment totaled about US$157.1M for product development; FY2026 guidance is US$950–970M revenue and US$200–240M pipeline R&D spend.

Positive

• Revenue +56% to US$803.8M in FY2025
• Precision Medicine revenue +22% year‑over‑year
• RLS segment revenue of US$238.4M and positive EBITDA
• FY2026 revenue guidance of US$950–970M

Negative

• Loss before tax of US$5.3M in FY2025
• Cash used in operating activities of US$(17.3)M
• US$246.4M of strategic M&A reduced year‑end cash
• Non‑cash finance costs of US$26.7M increased finance expense

Key Figures

FY 2025 Revenue: US$803.8M FY 2025 Adjusted EBITDA: US$39.5M Loss before income tax: US$5.3M +5 more

8 metrics

FY 2025 Revenue US$803.8M Group revenue for year ended Dec 31, 2025; up 56% vs 2024

FY 2025 Adjusted EBITDA US$39.5M Adjusted EBITDA for FY 2025 reflecting higher operating spend

Loss before income tax US$5.3M FY 2025 loss before tax including US$26.7M non-cash finance costs

Year-end cash balance US$141.9M Cash at Dec 31, 2025 after US$246.4M strategic investments

Precision Medicine gross margin 64% Precision Medicine segment gross margin, described as stable

Precision Medicine EBITDA US$216.4M Adjusted segment EBITDA, up 24% year-over-year

FY 2026 Revenue guidance US$950–970M FY 2026 Group revenue guidance range

FY 2026 R&D guidance US$200–240M Guided pipeline R&D expenditure for FY 2026

Market Reality Check

Price: $6.71 Vol: Volume 146,224 is at 0.79...

normal vol

$6.71 Last Close

Volume Volume 146,224 is at 0.79x the 20-day average 184,738 ahead of results. normal

Technical Shares at 6.71 trade below 200-day MA of 11.49 and 77.9% below the 52-week high 30.36.

Peers on Argus

TLX was up 4.68% with mixed peer action: RARE up 6.96%, APLS up 3.4%, while LGND...

TLX was up 4.68% with mixed peer action: RARE up 6.96%, APLS up 3.4%, while LGND and MLTX were down, indicating a stock-specific move rather than a clear sector rotation.

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Regulatory submission	Positive	-1.8%	Filed European MAA for TLX101-Px, aligned with U.S. NDA preparation.
Feb 03	Results webcast notice	Neutral	-0.1%	Announced timing of FY 2025 results and investor webcast details.
Jan 20	Revenue update	Positive	-0.4%	Reported unaudited FY 2025 revenue ~US$804M, meeting upgraded guidance.
Jan 16	Clinical trial start	Positive	+4.4%	First U.S. patient dosed in BiPASS Phase 3 prostate cancer diagnosis trial.
Jan 08	Conference presentation	Positive	+1.7%	Planned JP Morgan conference presentation and upcoming Q4 2025 financials release.

Pattern Detected

Recent fundamentally positive announcements (revenue beats, regulatory and clinical milestones) have often seen muted or even negative next-day moves, with a roughly even split between alignment and divergence.

Recent Company History

Over the last few months, Telix reported strong FY 2025 revenue of ~US$804M and reiterated growth via Gozellix and Illuccix, yet shares often moved only modestly. Regulatory and clinical updates, including a European MAA for TLX101-Px and first dosing in the BiPASS Phase 3 trial, produced mixed price reactions. This FY 2025 report extends the narrative of commercial expansion alongside heavy R&D investment.

Market Pulse Summary

This announcement highlights FY 2025 revenue of US$803.8M (up 56%), stable 64% gross margin in Preci...

Analysis

This announcement highlights FY 2025 revenue of US$803.8M (up 56%), stable 64% gross margin in Precision Medicine, and FY 2026 revenue guidance of US$950–970M alongside planned R&D spend of US$200–240M. Recent history shows consistent commercial growth coupled with intensive pipeline investment across multiple late-stage and first-in-human trials. Key factors to watch include progress on NDA/BLA submissions, clinical milestones, and how operating leverage develops against rising R&D and manufacturing costs.

Key Terms

adjusted EBITDA, marketing authorization application, new drug application (nda), biologics license application (bla), +4 more

8 terms

adjusted EBITDA financial

"Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

marketing authorization application regulatory

"Telix has filed a marketing authorization application for TLX101-Px in Europe"

A marketing authorization application is a formal request submitted to a government regulator asking permission to sell a prescription medicine or medical product in a country or region. Think of it like asking for a business license after showing evidence the product is safe and works; investors care because approval determines whether the product can generate sales, how soon revenue starts, and how much regulatory risk and uncertainty remains.

new drug application (nda) regulatory

"finalizing the New Drug Application (NDA) package for the U.S. Food and Drug Administration"

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

biologics license application (bla) regulatory

"issues for the Biologics License Application (BLA) resubmission, including demonstration of drug product"

A biologics license application (BLA) is a formal request to a government agency seeking approval to sell a biological medicine, such as vaccines or gene therapies, in the market. It is similar to a detailed report that proves the product is safe, effective, and manufactured properly. For investors, a BLA signifies a critical step toward commercial availability, often impacting a company's valuation and market prospects.

phase 3 medical

"ProstACTae Global10 Phase 3 study in metastatic castration resistant prostate cancer"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 2/3 medical

"LUTEON12, a global Phase 2/3 monotherapy trial in metastatic clear cell renal cell carcinoma"

A phase 2/3 trial is a combined clinical study that first evaluates how well a treatment works and the best dose, then expands into a larger test to confirm those results and safety. For investors, it matters because moving into a phase 2/3 signals that an experimental therapy has shown initial promise and will be tested at scale, which can materially change the odds and timeline for regulatory approval and commercial potential.

first-in-human (fih) medical

"AlphaPRO15, a Phase 1, first-in-human (FIH) study of Telix's targeted alpha therapy"

The first-in-human (FIH) designation marks the first time a new drug, vaccine, medical device, or treatment is given to people rather than tested only in labs or animals. For investors, FIH is a major milestone because it moves a candidate from preclinical testing into human safety and early effectiveness evaluation—think of it as the prototype being driven on public roads, where results strongly influence future development costs, timelines, and commercial potential.

pivotal trial medical

"to commence the IPAX-BrIGHT14 pivotal trial of TLX101-Tx in recurrent glioblastoma"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

AI-generated analysis. Not financial advice.

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025.

FY 2025 key results¹

Group performance²: Double-digit revenue growth and positive adjusted operating cash flow

• Revenue of US$803.8 million, up by 56%³ and achieving upsized full year guidance⁴.
• US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets⁵, in line with stated FY 2025 guidance.
• Adjusted EBITDA⁶ of US$39.5 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure and research and development (R&D).
• A non-material loss before tax of US$5.3 million, includes US$26.7 million in non-cash finance costs associated with convertible bonds and increased asset amortization of US$11.9 million (2024: US$5.1 million) following the RLS Radiopharmacies (RLS) acquisition.
• Year-end cash balance of US$141.9 million following US$246.4 million of strategic investments (M&A) and cash generated from operating activities of US$34.5 million before the final contingent consideration payment to Advanced Nuclear Medicine Ingredients (ANMI) of US$51.8 million⁷.

Telix Precision Medicine: Strengthening commercial profitability, driving growth

• Precision Medicine segment revenue up by 22% year-over-year, driven by continued increase in Illuccix® volumes and successful launch of Gozellix® in the U.S.
• Gross margin remains stable at 64%.
• Adjusted (segment) EBITDA up by 24% year-over-year to US$216.4 million.
• Selling and marketing expenses of US$82.4 million, reflecting incremental investment in global commercial infrastructure for new product launches (Illuccix EU, Gozellix, Zircaix®⁸ and Pixclara®⁸).
• TLX101-Px (Pixclara⁸) regulatory filings: Telix has filed a marketing authorization application for TLX101-Px in Europe, concurrent to finalizing the New Drug Application (NDA) package for the U.S. Food and Drug Administration (FDA).
• TLX250-Px (Zircaix⁸) submission: Based on the two Type A meetings with the FDA, Telix believes it has aligned on key outstanding issues for the Biologics License Application (BLA) resubmission, including demonstration of drug product comparability between clinical trial material and scale-up commercial production. The Company is now completing the agreed deliverables and documentation required for resubmission.

Telix Manufacturing Solutions (TMS): Expanded global operations to deliver patient outcomes

• TMS segment includes RLS, IsoTherapeutics (TX, U.S.), and production (and R&D) facilities in Sacramento (CA, U.S.), Brussels (Belgium), North Melbourne (Australia) and Yokohama (Japan), representing a significantly expanded global production and manufacturing footprint.
• RLS reported US$238.4 million of total segment revenue, which includes US$170.1 million from third-party product sales and service fees, and US$68.3 million inter-segment revenue⁹, reflecting excellent growth in sales of Illuccix and Gozellix through the RLS network.
• RLS transitioned to positive adjusted EBITDA contribution of US$1.2 million.
• RLS operating loss includes US$7.4 million of depreciation and amortization on acquired intangibles.
• Adjusted EBITDA loss for the TMS segment of US$21.7 million, expenditure consistent with first half, demonstrating inter-company cost control (H1 2025: Adjusted EBITDA loss of US$12.7 million).

Telix Therapeutics: Prioritization of R&D investment towards advancing late-stage assets

Of the total R&D investment, US$98.0 million was invested in the therapeutics pipeline. Milestones achieved include:

• TLX591-Tx (lutetium (¹⁷⁷Lu) rosopatamab tetraxetan): Completed target enrollment of 30 patients for Part 1 of the ProstACT® Global¹⁰ Phase 3 study in metastatic castration resistant prostate cancer (mCRPC). First patients treated in Part 2 (randomized expansion)¹¹.
• TLX250-Tx (¹⁷⁷Lu-DOTA-girentuximab): Received regulatory approval to commence LUTEON¹², a global Phase 2/3 monotherapy trial in metastatic clear cell renal cell carcinoma (ccRCC), initiating sites. First patients dosed in the STARLITE-1¹³ Phase 1b/2 investigator-initiated trial exploring TLX250-Tx in combination with cabozantinib and nivolumab in ccRCC.
• TLX101-Tx (iodofalan ¹³¹I): Received regulatory approval in Australia and the European Union to commence the IPAX-BrIGHT¹⁴ pivotal trial of TLX101-Tx in recurrent glioblastoma (GBM).
• TLX592-Tx (²²⁵Ac-PSMA-RADmAb): Received regulatory approval to commence AlphaPRO¹⁵, a Phase 1, first-in-human (FIH) study of Telix's targeted alpha therapy (TAT) candidate in advanced mCRPC.
• TLX252-Tx (²²⁵Ac-DOTA-girentuximab): Received regulatory approval to commence ALPHIX¹⁶, a Phase 1, FIH study of Telix's TAT candidate for the treatment of patients with advanced metastatic kidney cancer and other carbonic anhydrase IX (CAIX) expressing cancers.
• TLX300-Px (⁸⁹Zr-olaratumab): First patients dosed in the ZOLAR¹⁷ Phase 1, FIH imaging study for patients with advanced, metastatic soft tissue sarcoma (STS) and other platelet derived growth factor receptor alpha (PDGFRα) positive tumors, aiming to demonstrate proof of concept for therapy.
• TLX090-Tx (¹⁵³Sm-DOTMP): First U.S. patients dosed in SOLACE¹⁸, a Phase 1 study evaluating safety, dosimetry, patient‑reported outcomes, and potential opioid‑sparing effects of TLX090‑Tx in patients with metastatic bone pain.

FY 2026 Guidance

• Telix provides FY 2026 Group Revenue guidance of US$950 million to US$970 million.
• Guidance reflects revenue from product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS.
• Telix provides pipeline R&D expenditure guidance of US$200 million to US$240 million.

Executive Commentary

Managing Director and Group CEO, Dr. Christian Behrenbruch, commented on the result: “Our strong commercial performance in 2025 provides a platform for continued growth across Telix’s global Precision Medicine franchise. The revenue guidance we are issuing today reflects our confidence in sustaining the momentum of our core cash generative business. Consistent with our stated strategy, we are reinvesting earnings to prioritize the acceleration of our best-in-class therapeutic pipeline, which now includes three pivotal stage trials in prostate, kidney and brain cancer. We also intend to continue to expand the Precision Medicine growth opportunity through label expansion studies and new product launches. In 2026 we are focused on delivery of these near‑term priorities to further strengthen the foundations for long‑term revenue and earnings growth.”

Summary: Group financial results

	2025		2024
	US$M		US$M
Revenue	803.8		516.6
Cost of sales	(377.4	)	(180.4	)
Gross profit	426.4		336.2
Research and development	(171.2	)	(127.9	)
Selling and marketing	(96.8	)	(56.0	)
Manufacturing and distribution	(44.6	)	(16.7	)
General and administration	(95.7	)	(85.3	)
Other gains (net)	11.7		4.9
Operating profit	29.8		55.2
Finance income	5.8		7.2
Finance costs	(40.9	)	(24.4	)
(Loss)/profit before income tax	(5.3	)	38.0
Adjusted EBITDA19	39.5		66.9
Cash (used in)/from operating activities	(17.3	)	27.5

Investor call

An investor webcast and conference call will be held at 9:30 a.m. AEDT on Friday 20 February 2026 (5:30 p.m. EST Thursday 19 February 2026).

Participants can register for the webcast or the teleconference by clicking here: https://edge.media-server.com/mmc/p/famdpwzh

To read or download the 2025 Annual Report and to view the accompanying investor presentation, visit Telix's Investor Relations website: ir.telixpharma.com/

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Canada, Europe (Belgium and Switzerland), Brazil and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA.

Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com	Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com	Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its commercial products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Non-IFRS Financial Measures. Telix’s results are reported under International Financial Reporting Standards (IFRS). This announcement includes various non-IFRS financial information to reflect its underlying performance, which have not been subject to audit or review. These non-IFRS measures include Adjusted EBITDA, which represents net earnings attributable to the Group excluding net finance costs, income tax expense, depreciation and amortization and other gains/(losses) (net). As required by SEC rules, we have provided reconciliations of these non-IFRS financial measures to the most directly comparable IFRS measures, which for Adjusted EBITDA, is Profit/(loss) before income tax. The Group believes that these non-IFRS measures, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The non-IFRS measures are not defined by IFRS and therefore may not be directly comparable with other companies’ alternative performance measures.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

---

¹ See summary Group financial results table at end of this document.
² Group performance includes Telix Precision Medicine, Telix Therapeutics and Telix Manufacturing Solutions (TMS).
³ All comparisons to FY 2024 results.
⁴ Revised FY 2025 revenue guidance of US$800 million to US$820 million.
⁵ US$14.1 million of inventory for TLX250-Px (Zircaix®) commercial launch is additionally expensed to R&D. This expense arises from commercial inventory produced in anticipation of Zircaix approval and will be reversed upon FDA approval if received.
⁶ Earnings before interest, tax, depreciation and amortization.
⁷ In 2018, Telix acquired ANMI, the developer of the underlying Illuccix technology. The acquisition agreement included contingent consideration (variable payments) based on Illuccix global sales for five years following marketing authorization of Illuccix, with an option to buy out remaining payments in the third year following marketing authorization if agreed sales thresholds were met. As a result of strong sales performance, Telix successfully exercised its option to buy-out the remaining variable payments. The final payment of US$51.8 million comprising the option payment and third and final annual variable payment was made in July 2025, and is reflected in the cash flows for H2 2025, included in the Company’s full year financial results.
⁸ Launch and brand names subject to final regulatory approval.
⁹ Inter-segment revenue is eliminated on consolidation, refer to note 3 of the financial statements lodged today with the ASX.
¹⁰ Telix ASX disclosure August 21, 2025. ClinicalTrials.gov ID: NCT06520345.
¹¹ Telix media release December 8, 2025.
¹² ClinicalTrials.gov ID: NCT07197580.
¹³ ClinicalTrials.gov ID: NCT05663710.
¹⁴ ClinicalTrials.gov ID: NCT07100730.
¹⁵ Telix ASX disclosure August 21, 2025.
¹⁶ Telix ASX disclosure January 20, 2026.
¹⁷ Telix media release April 2, 2025. ClinicalTrials.gov ID: NCT06537596.
¹⁸ Telix media release October 23, 2025. ClinicalTrials.gov ID: NCT07197645.
¹⁹ Earnings before interest, tax, depreciation and amortization and other gains/(losses) (net).

FAQ

What were Telix (TLX) FY2025 total revenues and growth rate?

Telix reported US$803.8 million in FY2025 revenue, a 56% increase year‑over‑year. According to the company, growth was driven by higher volumes of Illuccix and launches including Gozellix and expanded RLS sales.

How profitable was Telix (TLX) in FY2025 and what was adjusted EBITDA?

Telix recorded an FY2025 adjusted EBITDA of US$39.5 million, with a small loss before tax of US$5.3 million. According to the company, higher operating spend and non‑cash finance costs weighed on statutory profit.

What guidance did Telix (TLX) give for FY2026 revenue and R&D spending?

Telix guided FY2026 revenue of US$950–970 million and pipeline R&D of US$200–240 million. According to the company, guidance includes a full year contribution from RLS and expected product sales in authorized jurisdictions.

What drove Telix (TLX) cash position and year‑end liquidity in 2025?

Year‑end cash was US$141.9 million after US$246.4 million of strategic M&A investments. According to the company, M&A activity and contingent consideration payments materially affected operating cash flow.

How did Telix’s Precision Medicine segment perform in FY2025 (TLX)?

Precision Medicine revenue increased 22% with a stable gross margin of 64% and segment adjusted EBITDA of US$216.4 million. According to the company, growth reflected Illuccix volume increases and the U.S. launch of Gozellix.

What key pipeline milestones did Telix (TLX) announce in the FY2025 results?

Telix reported multiple regulatory approvals and trial progress, including enrollment progress in ProstACT Phase 3 and filings for TLX101‑Px in Europe. According to the company, several Phase 1–3 trials advanced across prostate, kidney, and brain cancer programs.